The Asia Pacific insulin market size is expected to reach USD 7.09 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging markets such as India and China is expected to drive market growth during the forecast period. Furthermore, patent expiration of key products such as Lantus is expected to trigger the manufacturing of biosimilars from local manufacturers such as Biocon.
Asia Pacific Insulin Market Report Highlights
- The long-acting segment dominated the regional market in 2023 with a share of 53.07%. This growth is primarily driven by the rising need for long-acting insulin due to applications in Type I diabetes and II diabetes across the region and the globe.
- In 2023, the insulin analog segment held the largest revenue share of 88.6%. Insulin analog is created to mirror the pancreas' natural insulin release pattern, effectively regulating the body's blood sugar levels.
- The market share for type I diabetes in the Asia Pacific region reached 79.03% in 2023. Type I diabetes application is further projected to experience substantial expansion as a result of the increasing incidence of type I diabetes in children and teenagers.
- The retail & specialty pharmacies segment led the market and accounted for a revenue share of 89.9% in 2023. Looking toward the future, these pharmacies are projected to experience substantial growth.
For More Details or Sample Copy please visit link @: Asia Pacific Insulin Market Report
Long-acting analog dominated the overall market in terms of revenue share in 2013, with revenue estimated at USD 2,051.9 million. High prices coupled with relatively higher efficacies exhibited by these products account for its large share. Rapid-acting analogs followed the long-acting segment in 2013 accounting for a revenue share of over 25.0% on account of their high market penetration rates in developed markets such as Australia and Japan.
List of major companies in the Asia Pacific Insulin Market
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Biocon
- Boehringer Ingelheim International GmbH
- The United Laboratories International Holdings Ltd.
- Tonghua Dongbao Pharmaceutical Co. Ltd.
- Gan & Lee Pharmaceuticals
For Customized reports or Special Pricing please visit @: Asia Pacific Insulin Market Analysis Report
We have segmented Asia Pacific insulin market report based on product, type, application, distribution, and country.
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Contact:
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
#AsiaPacificHealthcare #InsulinMarket #DiabetesCare #InsulinTherapy #DiabetesManagement #PharmaAsia #HealthcareAsia #MedicalInnovation #DiabetesTreatment #Pharmaceuticals #InsulinPen #Type1Diabetes #Type2Diabetes #Endocrinology #APACHealthcare #DiabetesPrevention #BloodSugarControl #InsulinDemand #HealthTechAsia #ChronicDiseaseManagement
The rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care.
Also, advancements in technologies have ensured the introduction of highly flexible solutions in the market.
These are the major factors driving the growth of the global digital diabetes management market.
The increasing adoption of cloud-based enterprise solutions and the growing use of connected devices and apps are some of the other major factors supporting market growth.
Digital diabetes management solutions are smartphone-connected diabetes management devices and software platforms used by patients suffering from Type 1, Type 2, and gestational diabetes.
This study involved the extensive use of both primary and secondary sources.
According to the new market research report “Diabetes Care Devices Market by Type (SMBG, CGMS, Lancets, Insulin Pumps, Insulin Pens, Insulin Syringes, Mobile Apps), Patient Care Settings (Hospitals & Specialty Clinics, Self & Home Care), and Country (Brazil, Russia, India, China) – Forecast to 2025″, published by MarketsandMarkets™, the Diabetes Care Devices ((BRIC) Market size is projected to reach USD 4.3 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 16.2% during the forecast period.Browse in-depth TOC on “Diabetes Care Devices Market”64 – Tables42 – Figures168 – PagesDownload PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=375Factors such as the increasing diabetic population, rising awareness of diabetes treatment and management, and favorable national health strategies are expected to drive the growth of the diabetes care devices (BRIC) market.The blood glucose monitoring systems segment is estimated to dominate the diabetes care devices market in 2020Based on type, the diabetes care devices (BRIC) market has been segmented into blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications.
Under the blood glucose monitoring systems segment, the test strips segment is estimated to account for the largest share in 2020.
The dominance of this segment can be attributed to the frequent requirement of test strips in blood glucose monitoring systems.Self/home healthcare is projected to witness the highest CAGR in the diabetes care devices (BRIC) market during the forecast periodBased on end user, the diabetes care devices market has been segmented into hospitals & specialty clinics and self/home healthcare.
The self/home healthcare segment is estimated to hold the largest share in 2020.
This segment is also projected to grow at the highest CAGR during the forecast period.
The rapid growth of the segment is attributed to the increasing awareness of diabetes self-monitoring and management, increasing recommendations from physicians for home healthcare for diabetes, and the increasing utility of home-based diabetes care devices to provide real-time insights regarding the condition due to the technological advancements of these systems.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=375China to hold the largest share in the market in 2020, followed by IndiaChina is projected to hold the largest share in the diabetes care devices (BRIC) market during the forecast period.
Diabetes Reversal without medication; Affordable & complete diabetes treatment in Kochi; Consult dr.James Sebastian is the best diabetologist in kalamassery, KochiDiabetes mellitus refers to a group of diseases that affect how your body uses blood sugar (glucose).
Glucose is vital to your health because it’s an important source of energy for the cells that make up your muscles and tissues.
It’s also your brain’s main source of fuel.
The underlying cause of diabetes varies by type.
But, no matter what type of diabetes you have, it can lead to excess sugar in your blood.
Chronic diabetes conditions include type 1 diabetes and type 2 diabetes.
